期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伊马替尼治疗Ph阳性慢性粒细胞白血病后出现Ph阴性染色体异常 被引量：1

原文传递
导出
摘要 大约4．5％的慢性粒细胞白血病（CML）患者接受伊马替尼治疗后出现Ph阴性染色体异常（Ph-／cA），最常见的类型为＋8和-7等，大多为暂时性，少数病例可转化为骨髓增生异常综合征或急性髓细胞白血病。其发生机制可能与伊马替尼抑制Ph阳性克隆从而暴露Ph-／CA或伊马替尼的直接作用有关。接受伊马替尼治疗的CML患者应定期进行常规细胞遗传学分析，以及早发现Ph～／CA并长期监测其演变。
作者 韩永胜(综述) 薛永权(审校)
机构地区 苏州大学附属第一医院 江苏省血液研究所
出处 《国际输血及血液学杂志》 CAS 2009年第3期233-236,共4页 International Journal of Blood Transfusion and Hematology
关键词 伊马替尼 Ph阴性染色体异常 临床分析 治疗方法
分类号 R979.1 [医药卫生—药品] R596.1 [医药卫生—内科学]
  • 相关文献

参考文献39

  • 1Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood, 2007, 110(8): 2828-2837.
  • 2Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemianet. Blood, 2006, 108(6):1809-1820.
  • 3Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia, 2002, 16(7): 1390-1393.
  • 4Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol, 2003, 31(8): 702-707.
  • 5O' Shea D, Crotty G, Carroll P, et al. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance? Br J Haematol, 2004, 127(3) :367-369.
  • 6Deininger MW, Cortes J, Paquette R, et al. The prognosis for patients with chronic myetoid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative ceils. Cancer, 2007, 110(7) :1509-1519.
  • 7Terre C, Eelache V, Rousselot P, et al. Report of 34 patients with elonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of philadelphia-positive chronic myeloid leukemia. Leukemia, 2004, 18(8) : 1340-1346.
  • 8Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during irnatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98(9) : 1905-1911.
  • 9Lin Y, Bruyere H, Horsman DE, et al. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer genet cytogenet, 2006, 170(1):16-23.
  • 10Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2007, 110(8): 2991-2995.

二级参考文献13

  • 1Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med, 2002, 346:645-652.
  • 2Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002,99:1928-1937.
  • 3Sawyers CL, Hochhaus A, Feld E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase Ⅱ study. Blood, 2002,99:3530-3539.
  • 4Kantarjian HM, O' Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer, 2003,98:2636-2642.
  • 5Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase. Cancer,2003, 98:1905-1911.
  • 6Gozzetti A, Tozzuoli D, Crupi R, et al. Emergence of Ph negative clones in chronic myeloid leukemia (CML)'patients in complete cytogenetic remission after therapy with imatinib mesylate (STI). Eur J Haematol, 2003, 71:313-314.
  • 7Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph - , trisomy -8 + cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol, 2003, 31:702-707.
  • 8O' Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia, 2003, 17:481-487.
  • 9Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 2003, 101:1941-1949.
  • 10Fayad L, Kantarjian HM, O' Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia, 1997, 11:767-771.

共引文献9

同被引文献20

  • 1江倩,陈珊珊,江滨,江浩,陆颖,丘镜莹,陆道培.Ph阳性慢性粒细胞白血病患者伊马替尼治疗后的Ph阴性异常克隆演变[J].中华血液学杂志,2005,26(1):23-26. 被引量：10
  • 2SavageDG, AntmanKH. Imatinib mesylate--a new oral targeted therapy[J]. N Engl J Med, 2002, 346(9):683-693. doi: 10.1056/NEJMra013339.
  • 3DrukerBJ, TalpazM, RestaDJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. N Engl J Med, 2001, 344(14):1031-1037. doi: 10.1056/NEJM200104053441401.
  • 4JabbourE, KantarjianHM, AbruzzoLV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase[J]. Blood, 2007, 110(8):2991-2995. doi: 10.1182/blood-2007-01-070045.
  • 5ConchonMR, BenditI, FerreiraP, et al. Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors [J]. Int J Hematol, 2009, 89(1):123-125. doi: 10.1007/s12185-008-0224-y.
  • 6ZeidanA, KakatiS, AndersonB, et al. Monosomy 7 in t (9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case [J]. Cancer Genet Cytogenet, 2007, 176(2):169-171. doi: 10.1016/j.cancergencyto.2006.12.011.
  • 7BaldazziC, LuattiS, MarzocchiG, et al. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy [J]. Leuk Res, 2009, 33(12):e218-220. doi: 10.1016/j.leukres.2009.05.010.
  • 8BrothmanAR, PersonsDL, ShafferLG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition[J]. Cytogenet Genome Res, 2009, 127(1):1-4. doi: 10.1159/000279442.
  • 9BaccaraniM, DeiningerMW, RostiG, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013, 122(6):872-884. doi: 10.1182/blood-2013-05-501569.
  • 10AndersenMK, Pedersen-BjergaardJ, KjeldsenL, et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8[J]. Leukemia, 2002, 16(7):1390-1393. doi: 10.1038/sj.leu.2402634.

引证文献1

二级引证文献1

国际输血及血液学杂志
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部